Gemcitabine + Cisplatin + Sorafenib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extrahepatic Bile Duct Cancer
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Trial Timeline
Aug 1, 2009 → Mar 1, 2014
NCT ID
NCT00919061About Gemcitabine + Cisplatin + Sorafenib
Gemcitabine + Cisplatin + Sorafenib is a phase 2 stage product being developed by Bayer for Extrahepatic Bile Duct Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00919061. Target conditions include Extrahepatic Bile Duct Cancer, Gallbladder Cancer.
What happened to similar drugs?
0 of 1 similar drugs in Extrahepatic Bile Duct Cancer were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00919061 | Phase 2 | Completed |
Competing Products
4 competing products in Extrahepatic Bile Duct Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 40 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 35 |
| Gemcitabine + Cisplatin + Durvalumab | AstraZeneca | Phase 2 | 42 |
| aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil | Merck | Phase 2 | 35 |